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Adhesions complicate most intra-peritoneal operations. Once adhesions have formed, patients are at life-
long risk for complications that include small bowel obstruction, increased risks during subsequent
operations and female infertility. This has two implications for the daily work of surgeons. On the one
hand, surgeons need to include the risks from adhesions during pre-operative consent. On the other
hand, surgeons need to use operative techniques that minimize adhesions. Therefore this review focuses
on the practical implications of adhesions for preoperative consent and operative technique.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Post-operative adhesions result from a linear sequence of events
that is initiated by peritoneal trauma.1 Peritoneal trauma causes an
inﬂammatory reaction resulting in increased vessel permeability,
extravasation of immune cells and deposition of ﬁbrin. Usually
peritoneal ﬁbrinolytic activity rapidly eliminates deposited ﬁbrin
and prevents the formation of mature adhesions. However, in the
presence of ischemia or extensive tissue damage, as commonly
occurs after surgery, physiological ﬁbrinolysis can be insufﬁcient.2e
4 In this case ﬁbrin bridges form attachments between the trau-
matized areas and proximal tissues.5,6 Subsequent organization of
the ﬁbrin bridges by ﬁbroblast migration and vascularization under
the inﬂuence of speciﬁc growth factors then results in the forma-
tion of ﬁbrous adhesion tissue.7e9
When post-operative adhesions occur, they impose a signiﬁcant
burden on patients. The morbidity associated with adhesionsajab@gmail.com (T.K. Rajab).
ciates Ltd. Published by Elsevier Ltincludes small bowel obstruction, chronic pain and female infer-
tility.10e18 Moreover subsequent operations are more risky after
adhesions have formed. Adhesiolysis prolongs operating times,
increases complication rates and results in higher conversion rates
from laparoscopic to open surgery.14,19,20 From these risks follow
practical implications for preoperative consent and operative
technique.
2. Practical implications for preoperative consent
Surgeons have an established duty of care to give sufﬁcient in-
formation to patients where a signiﬁcant risk has been established.
In spite of this, little data is available on the prominence given to
adhesion-related complications during the consent process.
A survey sent online to UK surgical trainees showed that only 14%
would routinely warn patients undergoing laparotomy of the risks
from adhesions.21,22 These data are consistent with our own
experience that adhesions and adhesion-related complications are
infrequently discussed during pre-operative consent and rarely
documented in consent forms.23d. All rights reserved.
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process has to be considered relative to the risk to patients. After
lower abdominal surgery the re-admission rate directly related to
adhesions is 5% within 5 years.24 Within 10 years, 34% of patients
with open abdominal operations are re-admitted to hospital an
average of 2.1 times with a disorder related to adhesions or undergo
repeat surgery potentially complicated by adhesions.25
Adhesive bowel obstruction is of particular concern. This sur-
gical emergency has a mortality rate of 3% for simple obstruc-
tion,13,26 which escalates orders of magnitude when patients
present with perforation.13 The risk of adhesion related intestinal
obstruction after intra-peritoneal surgery is life-long. Follow-up of
laparotomy patients showed that 1%e7% develop adhesive
obstruction within 1e5 years of surgery.12,13,27,28 The incidence of
adhesive obstruction was 0.3%e10% within 4e6 years after ap-
pendectomy,27e30 around 6% within 5 years after open cholecys-
tectomy29 and 9%e25% within 2e10 years after bowel surgery
excluding appendectomy.27,28,31,32 This incidence is even higher in
particularly high risk surgeries, for example restorative proctoco-
lectomy, where adhesion related obstruction approaches 17%e25%
within 5e10 years.27,33e36
Guidelines advise doctors to inform their patients in writing if a
particular treatment might have serious adverse outcomes “even if
the likelihood is very small”.37 Less serious complications should be
mentioned if they are common. Legal precedent in the UK has
established failure of notifying a serious adverse event with a risk
greater than 1e2% as negligent (Chester v. Afshar, [2004] UKHL 41).10
Since then courts in the US have adopted an even tougher stan-
dard,38,39 which was established in a landmark Federal case (Can-
terbury v. Spence, 464 F.2d 772, 1972). Here the decision about
whether patients have to be informed of a risk is based onwhether a
reasonable person in the same position would want to be informed.
In the lightof these considerations it is clear that the level of risk from
adhesion-related complications is one of which patients should be
made aware.10,14,24,27,28,40e42 Therefore surgeons have an obligation
to advise patients regarding adhesions and the life-long risk of
problems caused by adhesions.43 Surgeonsmay alsowish to tell their
patients what they are going to do to minimize adhesion formation.
3. Practical implications for surgical technique
In order to minimize adhesions, surgical technique is
pivotal.41,44 The aims of successful surgical technique are to mini-
mize peritoneal insult in the form of mechanical, chemical and
exposure related trauma. To this end, the duration of surgery and
the traumatic insult should be minimized.1 Desiccation of tissue
should be avoided by usingmoist sponges.45 Surgeons should avoid
leaving devascularized or ischemic tissue behind, since this tissue is
highly adhesiogenic.46 The foreign body reaction from suture ma-
terial, which is known to trigger adhesion formation, should be
minimized by selecting ﬁne and non-reactive sutures, cut as short
as is consistent with a stable knot.47 Bleeding should be minimized
andmeticulous irrigation should be used to limit ﬁbrin deposition.6
Finally, powdered gloves should not be used.48,49
In addition to general minimally traumatic surgical technique,
speciﬁc adjuncts for intra-operative adhesion prophylaxis have
become commercially available. Pharmacological agents for adhe-
sion prevention have been a focus of intensive research.50,51 In spite
of this, physical barriers remain the only licensed agents for
adhesion reduction in the USA and Europe. These agents are
designed to decrease adhesiogenesis by preventing the formation
of ﬁbrin bridges from traumatized areas to surrounding tissues.52
The most commonly used adhesion barriers are Sepraﬁlm,
Adept and Interceed. Sprayshield is a barrier agent that was
introduced more recently.3.1. Sepraﬁlm
Sepraﬁlm (Genzyme, Cambridge, MA) is a solid adhesion
barrier consisting of chemically derived sodium hyaluronate and
carboxymethylcellulose. Its use is supported by a relatively strong
evidence base.53e56 Sepraﬁlm is the only agent proven to reduce
the incidence of small bowel obstruction under certain circum-
stances. Trials showed a reduction in adhesive small bowel
obstruction after intestinal resection55 and gastrointestinal sur-
gery.56 In a third study focusing on obstruction following gas-
trectomy for malignancy the beneﬁt of Sepraﬁlm did not reach
statistical signiﬁcance.57 Application of Sepraﬁlm requires careful
handling because the ﬁlm is brittle and cracks easily. Furthermore
this material ﬁxes upon contact with moist tissue and cannot
easily be moved after application. Sepraﬁlm is therefore suitable
for open operations but routine laparoscopic use is tedious and
not commonly employed. It is also important to note that
Sepraﬁlm should not be used to protect bowel anastomoses as
this may increase the risk of anastomotic leaks.543.2. Adept
Adept (Innovata plc, Nottingham, UK) is a liquid agent which
is instilled into the peritoneal cavity prior to closure.60 It consists
of 4% icodextrin in an iso-osmotic electrolyte solution. Icodextrin
is a high-molecular weight glucose polymer which results in a
prolonged intraperitoneal residence time of the solution.58 Dur-
ing this time the abdominal organs are separated by ﬂotation. As
a result, Adept covers the whole abdominal cavity and need not
be applied locally to the traumatized areas. A Cochrane systematic
review has concluded that there is currently insufﬁcient evidence
for use of Adept or any other ﬂuid agent in reducing post-
operative adhesions.59 After the publication of this review a
randomized, double-blinded, controlled trial by Brown and
colleagues offered substantial evidence that Adept improves
adhesion scores compared to Ringer’s Lactate as assessed at
second-look laparoscopy.60 This study represents the largest trial
of a licensed adhesion reduction agent to date. However, these
patients were not followed up for the incidence of clinically
relevant end points such as small bowel obstruction or chronic
pain. Operative handling of Adept is simple as it is introduced via
instillation into the peritoneal cavity following laparoscopy
where it remains until absorption. It is important to carefully
close the abdominal wounds subcutaneously to prevent post-
operative leakage of the solution. For this reason, Adept is also
not well suited for laparotomy.3.3. Interceed
Interceed (Johnson & Johnson Medical, New Brunswick, NJ)
was introduced in 1990 as the ﬁrst resorbable solid barrier for
adhesion prophylaxis. It consists of oxidized regenerated cellulose
and rapidly changes into a gelatinous consistency upon contact
with body ﬂuids, thus providing a protective coating around
traumatized areas. Since its introduction a substantial body of
evidence was collected that supports the use of Interceed. A recent
meta analysis of the current data showed that Interceed signiﬁ-
cantly reduces adhesion formation.61 Another advantage of
Interceed is relatively easy handling in both open and laparoscopic
modalities. In spite of this, prolonged operative times were noted
following use in laparoscopy.62 Another drawback of the use of
Interceed is its loss of effectiveness with exposure to blood.63
Therefore, complete hemostasis must be achieved before Inter-
ceed is applied.
T.K. Rajab et al. / International Journal of Surgery 11 (2013) 753e756 755
REVIEW3.4. Sprayshield
Sprayshield (Covidien, Waltham, MA) consists of two modiﬁed
polyethylene glycol solutions with complementary end functional
groups (amines on one end and N-hydroxysuccinamide esters on
the other). When mixed at the site of application these solutions
react with each other to form an absorbable gel. This makes
Sprayshield very easy to use, even in laparoscopic surgery. Spray-
shield persists in the abdomen for up to 7 days and is afterwards
absorbed by the body and eliminated through the kidneys. Spray-
shield is a modiﬁcation of the adhesion barrier Spraygel, which
had been discontinued after disappointing results were published.
Meta analysis of the available human trials with Spraygel64,65 did
not show signiﬁcant adhesion reduction59 and a large scale pivotal
trial of Spraygel that had commenced in the USA was stopped due
to lack of efﬁcacy in the treatment arm.41 The differences between
Sprayshield and Spraygel include a shorter absorption time which
presumably decreases the body’s foreign body reaction and
changing the dye frommethylene blue to Brilliant Blue FCF. Further
clinical studies are necessary to determine the clinical efﬁcacy of
Sprayshield in human patients.
3.5. Advantages and disadvantages of using anti-adhesion agents
In order to make the decision whether an anti-adhesion agent
should be used, the surgeon needs to consider the advantages and
disadvantages to the patient and to the healthcare system. The
advantages for the patient includewell documented decrease in the
adhesion burden.66 There is also some evidence that these agents
decrease adhesion-related complications in humans,55 but this
evidence is limited. Potential disadvantages include the possibility
of allergic reactions to the prosthetic material and cost of the
anti-adhesion agent. Allergic reactions have been reported infre-
quently.67 Cost effectiveness of anti-adhesion products are a func-
tion of the cost of the agent itself minus the cost of adhesion-related
complications that are prevented. It has been estimated that an
agent reducing adhesion-related readmissions by 25% and costing
110 British Pound Sterling per patient would be cost-effective in the
British NHS.27 However, these calculations are based on estimates
that are based on limited evidence. Furthermore, similar calcula-
tions are missing for other important healthcare markets.
In the light of these advantages and disadvantages we suggest
that surgeons consider using anti-adhesion agents in procedures
that are particularly high-risk for adhesions and in young patients
who have a higher lifetime risk of adhesion related morbidity.
4. Conclusion
In summary, post-operative adhesions are frequent and cause
signiﬁcant long-term morbidity for patients. Even though
adhesion-related complications occur relatively late after the
original operation they should not be neglected during the pre-
operative consent process. This review has summarized the
available evidence that can be used to inform patients about the
frequency and severity of adhesion-related complications.
Furthermore, physical barriers that decrease adhesion formation
have become routinely available. While there is sufﬁcient data to
support the hypothesis that these barriers decrease adhesion for-
mation there is limited human evidence that the commercially
available adhesion barriers signiﬁcantly prevent adhesion-related
complications. Therefore, we recommend that physical barriers
be used in high-risk operations such as proctocolectomy, opera-
tions with planned multiple stages such as ileostomy for eventual
takedown as well as in young patients who have a high life-time
risk of developing complications from adhesions.Ethical approval
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